Enhertu (100 mg of fam-trastuzumab deruxtecan-nxki)

What is Enhertu (fam-trastuzumab deruxtecan-nxki) for?

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription medicine used to treat patients with HER2-positive:

• Breast cancer that cannot be removed by surgery (unresectable) or that has spread to other parts of your body (metastatic), who have received one or more prior anti-HER2 breast cancer treatments, either in the metastatic phase or in the early-stage setting.
• Stomach (gastric) or gastroesophageal junction adenocarcinoma that has spread to areas near the stomach (locally advanced) or is metastatic, and who have received a prior trastuzumab-based regimen.

How effective is Enhertu (fam-trastuzumab deruxtecan-nxki) for breast cancer?

The approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for breast cancer was based on a clinical study of 184 women with previously treated HER2+ unresectable or metastatic breast cancer. The study showed that:​​​

How effective is Enhertu (fam-trastuzumab deruxtecan-nxki) for stomach cancer?

The approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for stomach cancer was based on a study in 188 people with previously treated HER2+ advanced stomach cancer. Enhertu was compared with 2 commonly used chemotherapies (irinotecan or paclitaxel). The study showed that:​​​

• 40.5% saw their tumors shrink with Enhertu
• 11.3% saw this while receiving chemotherapy

• 84% had their tumors shrink, stop growing, or the growth of their tumors slowed with Enhertu
• 61% saw this while receiving chemotherapy

Enhertu helped people with stomach cancer live 4 months longer than with chemotherapy:

• Half of the people taking Enhertu were alive at 12.5 months
• Half of the people taking chemotherapy were alive at 8.4 months

Which side effects can I expect with Enhertu (fam-trastuzumab deruxtecan-nxki)?

According to the study results published, the most common side effects of Enhertu (fam-trastuzumab deruxtecan-nxki) in people with HER2-positive breast or gastric cancer include: nausea, fatigue, vomiting, hair loss, constipation, decreased appetite, low (white and/or red) blood cell counts, low platelet counts, diarrhea, cough, and thrombocytopenia.

Enhertu may cause fertility problems in males, which may affect the ability to father children. Talk to your treating doctor if you have concerns about fertility.

Please note this is not intended to be a comprehensive guide. Consult your treating doctor and the prescribing information at the bottom of the page for full details of side effects.

How is Enhertu (fam-trastuzumab deruxtecan-nxki) taken?

Administration: intravenous infusion (IV) once every 3 weeks.

Dosage: 5.4 mg/kg body weight.

Please note this is not intended to be a treatment plan. For a personalised treatment plan, consult your doctor. For more details, you can also reference the full prescribing information at the bottom of the page.